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Zijlstra LE, Jukema JW, Mooijaart SP, de Vries MA, Stott DJ,
Castro Cabezas M, Trompet S. Association of complement receptor
1 gene polymorphisms with cognitive function. Physiol Genomics 50:
102–103, 2018. First published December 6, 2017; doi:10.1152/
physiolgenomics.00102.2017.—Previous evidence suggest involve-
ment of the complement receptor 1 (CR1) in development of Alzhei-
mer’s disease. We investigated the association of CR1 gene polymor-
phisms with cognitive function in older subjects. Single nucleotide
polymorphisms (SNPs) within the CR1 region on chromosome 1 (n
73) were assessed in 5,244 participants in the PROspective Study of
Pravastatin in the Elderly at Risk (51.9% female, mean age 75.3 yr).
Linear regression, adjusted for age, sex, country, and use of prava-
statin, was used to assess the association between the SNPs and
cognitive function. All 73 SNPs within the genomic region of the CR1
gene on chromosome 1 were extracted. Eighteen were independent,
according to a relatively stringent R2 threshold of 0.8 with LDlink.
Twelve of the 18 investigated CR1 SNPs were significantly associated
with a decline in cognitive function (all P 0.05). These data indicate
that genetic variation within the CR1 gene is associated not only with
Alzheimer’s disease, but also with general cognitive function during
late life.
Alzheimer’s disease; chromosome 1; cognitive function; complement
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BACKGROUND/MOTIVATION FOR THE STUDY
Previous evidence suggest that the complement receptor 1
(CR1) may be involved in the development of multiple dis-
eases. For instance, as previously reported, genetic variation
within the CR1 gene is associated with inflammation and the
risk of incident coronary artery disease (5). Also, in multiple
genome-wide association studies (GWAS) concerning Alzhei-
mer’s disease (AD) the CR1 locus has been identified as a
candidate gene (3).
CR1 is a receptor for the complement proteins C3b and C4b.
The complement system is involved in the innate immune
system and functions as a first-line defense mechanism against
infection. The complement system can be activated via differ-
ent pathways, ultimately leading to activation of the protein
C3, which is split into C3b and C3a. This leads to the facili-
tation of opsonization and phagocytosis of pathogens. Via the
CR1 receptor, circulating erythrocytes can carry immune com-
plexes and opsonized microorganisms to these phagocytic
cells.
As described in a review by Alexander et al. (1) previous
studies have described the complement system as not only
involved in regulation of the innate immunity but also playing
a role in the nervous system and therefore neurological disor-
ders. As mentioned above, the CR1 gene has been associated to
AD, a neurogenerative disease that is the most common cause
of dementia in older patients. There is also evidence that
variation within the CR1 gene is associated with general loss of
cognitive function, which is the first clinical presentation of
AD. For instance, Chibnik et al. (2) found an association
between variation in CR1 (rs6656401) with cognitive aging in
the general population.
Therefore, we investigated the association of CR1 gene
polymorphisms with cognitive function in older patients.
PHENOTYPE
We investigated the association of CR1 gene polymorphisms
with cognitive function decline. A detailed description of how
cognitive function was measured has been published previ-
ously (4).
At baseline cognitive dysfunction was screened with the
Mini-Mental State Examination (MMSE). We used the gener-
ally accepted cut-off point of 24 (of 30) points. Participants
with a score below this cut-off at baseline were excluded from
PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER).
Outcome variables were derived from three other widely
used cognitive function tests.
First, selective attention was assessed by the Stroop Color
Word Test, which consists of three parts, namely color names,
colored patches, and color names printed in incongruously
colored ink. The time required to read the names or to identify
colors is recorded. We used an abbreviated version of the test
with 40 elements.
Second, the speed of processing of general information was
assessed with the Letter-Digit Coding Test, which is a modi-
fication of the procedurally identical Symbol-Digits Modalities
Test.
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Third, verbal learning was assessed using the Picture-Word
Learning Test, which is derived from the Groningen Fifteen
Words Test. Outcomes are measured in three different trials
and divided in recall and delayed recall after 20 min.
Cohort details. All data come from PROSPER, a study that
investigated the relationship between statin treatment and the
risk of coronary disease (n  5,804). Measurement of cogni-
tive decline was a prespecified end point. In summary, older
participants were enrolled in Ireland, Scotland, and The Neth-
erlands. Patients were included if they had a history of, or an
increased risk for, vascular disease and a baseline choles-
terol between 4.0 and 9.0 mmol/l. Of the 5,804 participants,
5,244 subjects were included for genetic analysis and 51.9%
was female with a mean age of 75.3  3.4 yr. Mean
follow-up was 3.2 yr. As mentioned above, one of the
exclusion criteria was poor cognitive function at baseline
(MMSE 24). Detailed description, including all other in-
and exclusion criteria, has been published previously (4).
Type of study. Candidate gene.
Details of the SNPs studied. From the GWAS, performed in
PROSPER, all 73 SNPs within the genomic region of the CR1
gene on chromosome 1 were selected with PLINK software.
According to LDlink, 18 SNPs were independent, taking a
relatively stringent R2 threshold of 0.8. Details have been
described previously.
A list of all 18 SNPs and additional references are included
in the data supplement. (The online version of this article
contains supplemental material.)
Analysis model. Allele frequencies were estimated, and pair-
wise linkage disequilibrium (LD) between the investigated
SNPs was estimated and plotted with the program Haploview.
Associations between the CR1 SNPs and cognitive function
were assessed with linear regression adjusted for sex, age,
country, and treatment with pravastatin. PLINK statistical
software was used for performance of all statistical analyses.
RESULTS
All SNPs were in Hardy Weinberg equilibrium (P  0.05).
The results of the association between the 18 CR1 SNPs and
four cognitive performance tests showed significant associa-
tions for 12 out of the 18 SNPs (all P  0.05). A negative
association with the Stroop Color Word Test indicates an
increase in cognitive function, which is in line with a positive
association for the other three tests. For nine SNPs the minor
allele frequency was associated with an increase in cognitive
function, whereas for three SNPs the minor allele frequency
was associated with a decrease. Furthermore, four SNPs
(rs9429944, rs4844599, rs11117956, rs12734030) showed sta-
tistical significant association with all four cognitive perfor-
mance tests. Details of these SNPs, including scores for all four
tests, are described in the results table in the online supplement.
INTERPRETATION
Twelve of the 18 investigated CR1 SNPs were significantly
associated with cognitive function. Therefore, these data indi-
cate that genetic variation within the CR1 gene is not only
associated with Alzheimer’s disease, but also with general
cognitive function decline during late life. Furthermore, three
of these 12 SNPs that were associated with improved cognitive
function were associated with lower levels of CRP (5). These
data further strengthen previous evidence of Alexander et al.
(1) for the role of the complement system in cognitive function.
However, future studies investigating the functionality of these
CR1 SNPs are necessary.
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